Liquidia Corporation (LQDA)
LQDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819576/000110465926023804/0001104659-26-023804-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LQDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001819576 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $158.3M |
| Net income | -$68.9M |
| Operating income | -$51.4M |
| Net margin | -43.5% |
| Operating margin | -32.5% |
| Revenue growth | +1031.2% |
| Cash | $190.7M |
| Total assets | $327.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 32.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $396.1M cash; operating cash flow $81.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 90,106,442 (2026-10-28); 86,995,483 a year earlier; 64,905,495 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $318K, sold $222.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $225.3M | -$236.3M | $146.7M | $396.1M | No debt tags | $621.9M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $171.7M | $74.7M | $80.2M | $284.2M | No debt tags | $450.9M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $132.9M | $52.9M | $53.0M | $222.8M | No debt tags | $288.1M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $92.0M | $14.6M | $44.2M | $190.7M | No debt tags | $158.3M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $54.3M | -$3.5M | -$9.8M | $157.5M | No debt tags | $69.2M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $8.8M | -$41.6M | -$39.5M | $173.4M | No debt tags | $19.3M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $3.1M | -$38.4M | -$30.7M | $169.8M | No debt tags | $14.1M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $2.9M | -$38.5M | -$20.8M | $176.5M | No debt tags | $14.0M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-05 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 704 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +29.3% |
| 1 month | +114.1% |
| 3 months | -20.4% |
| Year to date | +66.5% |
| 1 year | +113.1% |
| From 52-week high | -36.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier